These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29633692)

  • 1. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.
    Ferrari A; Manca M; Tugnoli V; Alberto L
    Funct Neurol; 2018; 33(1):7-18. PubMed ID: 29633692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type A products are not interchangeable: a review of the evidence.
    Brin MF; James C; Maltman J
    Biologics; 2014; 8():227-41. PubMed ID: 25336912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials.
    Prager W; Nogueira Teixeira D; Leventhal PS
    Dermatol Surg; 2017 Jul; 43(7):959-966. PubMed ID: 28375973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.
    Frevert J
    Drugs R D; 2015 Mar; 15(1):1-9. PubMed ID: 25559581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA.
    Kutschenko A; Manig A; Reinert MC; Mönnich A; Liebetanz D
    Neurosci Lett; 2016 Aug; 627():216-21. PubMed ID: 27268041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
    Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
    JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
    Matarasso A; Shafer D
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions.
    Aoki KR; Guyer B
    Eur J Neurol; 2001 Nov; 8 Suppl 5():21-9. PubMed ID: 11851731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of biological activity of four botulinum toxin type A preparations in mice.
    Chung ME; Song DH; Park JH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):155-64. PubMed ID: 23301819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
    Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
    Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum neurotoxin type A in facial aesthetics.
    De Boulle KL
    Expert Opin Pharmacother; 2007 Jun; 8(8):1059-72. PubMed ID: 17516871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis.
    Gilbert E; Ward NL
    J Drugs Dermatol; 2014 Nov; 13(11):1407-8. PubMed ID: 25607710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
    Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
    Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical resistance to three types of botulinum toxin type A in aesthetic medicine.
    Stephan F; Habre M; Tomb R
    J Cosmet Dermatol; 2014 Dec; 13(4):346-8. PubMed ID: 25399628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulism toxin in practice].
    Durand A; Serment G
    Ann Readapt Med Phys; 2003 Jul; 46(6):386-8. PubMed ID: 12928147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OnabotulinumtoxinA.
    Tepper D
    Headache; 2020 Nov; 60(10):2649-2650. PubMed ID: 33249584
    [No Abstract]   [Full Text] [Related]  

  • 20. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
    Ravindra P; Jackson BL; Parkinson RJ
    BJU Int; 2013 Jul; 112(1):94-9. PubMed ID: 23490404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.